

Resource Summary Report

Generated by [dkNET](#) on Sep 5, 2026

RM-1 [Mouse prostate carcinoma]

RRID:CVCL_B459

Type: Cell Line

Proper Citation

ATCC Cat# CRL-3310, RRID:CVCL_B459

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_B459

Proper Citation: ATCC Cat# CRL-3310, RRID:CVCL_B459

Description: Cell line RM-1 [Mouse prostate carcinoma] is a Cancer cell line with a species of origin *Mus musculus* (Mouse)

Sex: Male

Disease: Carcinoma of the mouse prostate gland

Defining Citation: [PMID:7538321](#)

Category: Cancer cell line

Organism: *Mus musculus* (Mouse)

Name: RM-1 [Mouse prostate carcinoma]

Synonyms: RM1

Cross References: BTO:BTO_0003780, ATCC:CRL-3310, CCRID:3101MOUTCM14, CLS:305168, Ubigene:YC-C049, Wikidata:Q54950629

ID: CVCL_B459

Vendor: ATCC

Catalog Number: CRL-3310

Record Creation Time: 20220427T221501+0000

Record Last Update: 20260904T015534+0000

Ratings and Alerts

No rating or validation information has been found for RM-1 [Mouse prostate carcinoma].

No alerts have been found for RM-1 [Mouse prostate carcinoma].

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 34 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Fan X, et al. (2026) CRISPR-Cas9-Loaded Theranostic Liposomes for Enhancing Radiosensitization of Prostate Cancer through POLD4 Gene Editing under Real-Time MRI Monitoring. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e19704.

Li H, et al. (2026) YEATS2 promotes DNA repair and induces anoikis resistance by enhancing chromatin accessibility to drive prostate cancer metastasis. *Oncogene*, 45(11), 971.

Zhang H, et al. (2026) ROS Cascade-Amplified Polymeric Nanosystem Exhibiting Multi-Pathway Induction of Immunogenic Cell Death and Chemotherapeutic Efficacy in Tumor. *Advanced healthcare materials*, 15(25), e71279.

Nasr MM, et al. (2026) PRDM16 Regulates Prostate Cancer Cell Dormancy and Prevents Bone Metastatic Outgrowth. *Cancer research*, 86(3), 604.

Brevi A, et al. (2026) Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression. *Cancer research*, 86(12), 2860.

Gao L, et al. (2026) Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer. *Journal for immunotherapy of cancer*, 14(1).

Jiao Y, et al. (2026) A Plasmonic "Lid-Off" Nanoplatfrom for Spatiotemporally Controlled PA/NIR-II Dual-Modal Imaging and Cuproptosis-Based Synergistic Photothermal and Chemodynamic Therapy. *Small* (Weinheim an der Bergstrasse, Germany), 22(37), e73776.

Ding J, et al. (2026) CDC20 promotes prostate cancer progression via modulating c-MYC and PI3K-AKT signaling. *iScience*, 29(7), 116409.

Liu S, et al. (2026) Betulinic acid induces lysosome-dependent death in prostate cancer by targeting DDX5. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 155, 158143.

Wang Y, et al. (2026) GUTK induces apoptosis in reactivating quiescent prostate cancer cells via Aurora A-mediated stabilization of SOD2. *iScience*, 29(5), 115739.

- Du Q, et al. (2026) Gasdermin D antagonizes immunosuppression in prostate cancer by inducing LAMC2 degradation to block M2 macrophage polarization. *Journal for immunotherapy of cancer*, 14(5).
- Di J, et al. (2026) Sequential nanocatalytic therapy and lysosomal dysfunction for overcoming castration-resistant prostate cancer. *Bioactive materials*, 64, 232.
- Wang Q, et al. (2025) AR+TREM2+ macrophage induced pathogenic immunosuppression promotes prostate cancer progression. *Nature communications*, 16(1), 6964.
- Sun F, et al. (2025) CAMK1D activates AMPK/PINK1/Parkin-dependent mitophagy to promote enzalutamide resistance in prostate cancer. *Cell death & disease*, 17(1), 113.
- Johnson CS, et al. (2025) Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer. *Molecular cancer research : MCR*, 23(8), 739.
- Salloom RJ, et al. (2025) Synergistic effects of HO-1 inhibition and chemotherapy on tumor proliferation and immune infiltration: An in vitro and in vivo approach to enhancing prostate cancer treatment. *Translational oncology*, 54, 102339.
- Mei S, et al. (2025) Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis. *Molecular cancer research : MCR*, 23(7), 653.
- Deng B, et al. (2025) PDGFC facilitates enzalutamide resistance in prostate cancer through activation of the Rap1-MAPK pathway. *Journal of cancer research and clinical oncology*, 151(10), 267.
- Duhan V, et al. (2025) FcR γ -Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity. *Cancer immunology research*, 13(12), 2075.
- Zhao T, et al. (2025) Derepressing nuclear pyruvate dehydrogenase induces therapeutic cancer cell reprogramming. *Cell metabolism*, 37(8), 1667.